Quince Therapeutics Inc - QNCX Quarterly EPS earnings growth

Quince Therapeutics - graphic logo of issuer QNCX

Under the leadership of Dirk Tilemans, the Quince Therapeutics (QNCX) team is integrating new clinical platforms while investors await the results of early tests. Quince Therapeutics (QNCX) is developing therapies for rare metabolic pathologies tailored for orphan centers. The quarterly EPS growth snapshot demonstrates profit dynamics, where the 82.70 mark reflects the latest data. Innovations in erythrocyte-based drug delivery are establishing the foundation for future royalties.

Quince Therapeutics, Inc. (QNCX) - Year-over-year earnings per share growth for the last twelve months from 04/28/2023 to 10/12/2026

Financial and market metric breakdowns for quincetx.com (QNCX)

- share price and consensus valuation forecast:
Analysis of all company metrics:Quince Therapeutics
Manufactured product of Quince Therapeutics

This indicator calculates the quarterly net profit per share dynamics, reflecting the sensitivity of final returns to changes in financial reporting. Analyzing the quarterly EPS gap allows for an assessment of the business predictability of Quince Therapeutics (QNCX), whose clinical trial outsourcing model minimizes capital expenditures, turning this chart into a tool for identifying undervalued assets with low drawdown risk.

Competitors of Quince Therapeutics (QNCX)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS